This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CardioNet, Rexahn Pharma: Volume Movers

Stocks in this article: BEAT RNN

NEW YORK ( TheStreet) -- CardioNet (BEAT) was one of several stocks moving on above-average volume Monday as concerns over national healthcare reimbursements for the medical technology company's services drove shares lower.

CardioNet said the Centers for Medicare and Medicaid Services (CMS) proposed that that the technical component of mobile cardiovascular telemetry remains carrier-priced for calendar year 2011. The CMS will give it final rule by Nov. 1 for implementation on Jan. 1, 2011, and if adopted means that local Medicare contractors will decide on reimbursement amounts.

"Given our efforts to obtain a national reimbursement rate for CardioNet's MCOTTM technology, we are disappointed in CMS' Proposed Rule," CardioNet CEO Joe Capper said in a statement. "We will work diligently during the public comments period to request that CMS change its recommendation to one that is more beneficial to Medicare recipients who depend on MCOTTM."

CardioNet shares were down 76 cents, or 10.6%, to $6.42. Volume topped 938,000 shares, compared to the 50-day average daily volume of 406,000, according to the Nasdaq.

Elsewhere, Rexahn Pharmaceuticals (RNN) dropped by 17 cents, or 9.9%, to $1.55 after the drug company said it has raised $10 million through a registered direct offering. Institutional investors bought units consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock at a purchase price of $1.50.

Rexahn said net proceeds of approximately $9.45 million will be used for further development of the company's lead clinical programs, including the funding of Rexahn's Phase II clinical study program of serdaxin, zoraxel and archexin.

Rexahn's volume topped 832,000 shares, compared to the three-month average daily volume of 2.13 million, according to Yahoo! Finance.

-- Written by Robert Holmes in Boston.

Follow Robert Holmes on Twitter and become a fan of on Facebook.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs